by Rod Raynovich | Mar 31, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Biopharmaceutical stocks caught bids today (in a weak technology market) after yesterday’s M&A spiked rally. Large cap leaders in the NASDAQ-100 were up: Biogen(BIIB) up 1.63%, Celgene (CELG) up 1.6% and Gilead (GILD) up 0.68%. Major ETF’s-IBB FBT XBI-...
by Rod Raynovich | Mar 30, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Optimer soars 11% to $13.13 on presentation of Shea Data and preliminary FDA review: Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients – Yahoo! Finance Optimer...
by Rod Raynovich | Mar 30, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Biopharmaceutical Stocks Ignited By M&A Potential M&A has been a key driver for investing in biotech stocks as need for product pipeline and technologies grows. The drug development process is slow and synergies can be found faster by buying companies on the...
by Rod Raynovich | Mar 29, 2011 | RAG
3/30/11 Update CEO Michael Pearson of Canadian based Valeant (VRX) reiterated his determination(live on CNBC this am) for buying Cephalon (CEPH) after being stalled by the Board of CEPH after initial discussions.Mr. Pearson stated he wanted to move quickly and if the...
by Rod Raynovich | Mar 29, 2011 | 2023-24 Life Science Portfolios, BIOgraph
As has been the pattern lately biotech sector rallies coincide with NASDAQ with the NAZ (2753) up 20.2 or 0.81% . The mid caps are the sweet spot in the market with as our mid-cap index of 33 biotechs are almost all green with the average up 1.57%. 14 of the stocks...
by Rod Raynovich | Mar 29, 2011 | 2023-24 Life Science Portfolios, BIOgraph
In January we reported from the JPMorgan Healthcare Conference regarding convergence of communications and medical technologies. Two trends mentioned were use of cloud computing and connectivity in medicine. Here is a brief update: Abbott (ABT $48) announced today...
by Rod Raynovich | Mar 28, 2011 | BIOgraph
Ariad (ARIA $7.24 up 4.3%) continues to roll on today on heavy volume up 17% over 5 days on speculation, news and upgrades with strong expectations for their chronic myeloid leukemia drug ponatinib. Articles from Motley Fool, Seeking Alpha and The Street.com have...
by Rod Raynovich | Mar 25, 2011 | Macro
Rick Santelli on CNBC answered the question today. Very few places to put your money: 1-In the mattress-cash. 2-In the ground-metals, energy. 3-In equities-earnings. With investors worried about interest rates rising and potentially no QE 3 , money could come out of...
by Rod Raynovich | Mar 24, 2011 | BIOgraph
On robust and active Life Science trading day two laggard diagnostic stocks perked up: Iris International (IRIS $9.41) is up 4.44% on FDA clearance of its iChem Velocity Workstation for automated Urine Chemistries. The stock is been trading from $9-10 over the past...
by Rod Raynovich | Mar 24, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Biotech rally day with speculative news: ASCO,M&A,and Clinical News. Biotech stocks were green across the board with our mid-cap index of 33 stocks up 1%. ETF’s were strong: FBT up 1.3%, IBB up 1.3% and XBI up 1.45%. The NAZ is up 1.11%. Some notable winners...